Advice

in the absence of a submission from the holder of the marketing authorisation

everolimus (Certican®) is not recommended for use within NHS Scotland.

Indication under review:
• Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a cardiac transplant
• Prophylaxis of organ rejection in patients receiving a hepatic transplant

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

NICE (National Institute for Health and Clinical Excellence) is currently undertaking a multiple technology appraisal (MTA) that includes the use of everolimus for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal transplant and therefore SMC has not issued advice for that indication.
 

Download detailed advice112KB (PDF)

Download

Medicine details

Medicine name:
everolimus (Certican)
SMC ID:
1117/15
Indication:
Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a cardiac transplant; Prophylaxis of organ rejection in patients receiving a hepatic transplant.
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
09 November 2015